Cost‐effectiveness of 18F‐fluorodeoxyglucose positron emission tomography in the assessment of early dementia from a Belgian and European perspective
The DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
Abstract
18 F‐fluoro‐deoxyglucose positron emission tomography (FDG PET) can aid to predict AD in an early stage. The aim of this study was to estimate the economic effects of incorporating FDG PET in the diagnostic work‐up of AD in a Belgian and European setting. A decision tree analysis was followed comparing a conventional algorithm using diagnostic clinical criteria and one that also incorporates PET. Major outcome terms were overall cost per patient in either strategy; diagnostic accuracy and cost per accurate diagnosis. A sensitivity analysis was performed for four critical variables: cost of PET, sensitivity and specificity of PET and delay in cognitive decline because of appropriate medication. Cost‐savings per accurate diagnosis ranged from 623–6110 Euro in favour of the proposed algorithm with PET. For the same cost, more accurate diagnoses were made, resulting in benefit for patients and society. The positive results were maintained over a wide range of values for the critical variables and were expandable to other European countries with a similar health system. Therefore, incorporation of FDG PET into the clinical diagnostic work up of patients with early symptoms of cognitive decline can be advocated.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Petersen, R. C., Stevens, J. C., Ganguli, M., Tangalos, E. G., Cummings, J. L., & DeKosky, S. T. (2001) · Neurology · doi:10.1212/wnl.56.9.1133 · Cited by 2,065
Knopman, D. S., DeKosky, S. T., Cummings, J. L., Chui, H., Corey–Bloom, J., Relkin, N., Small, G. W., Miller, B., & Stevens, J. C. (2001) · Neurology · doi:10.1212/wnl.56.9.1143 · Cited by 1,410
Rosler, M., Anand, R., Cicin-Sain, A., Gauthier, S., Agid, Y., Dal-Bianco, P., Stahelin, H. B., Hartman, R., Gharabawi, M., & Bayer, T. (1999) · BMJ · doi:10.1136/bmj.318.7184.633 · Cited by 943 · cited 1×
“…view of the increasing number of elderly at risk for AD, accurate and early diagnosis has become of primary importance (Rogers and Friedhoff, 1996; Sano et al., 1997; Burns et al., 1999; van Crevel et al., 1999; Rosler et al., 1999; Doody et al., 2001; Mohs et al., 2001; Silverman et al., 2002a).”
BackgroundRaskind (2000) · doi:10.1212/wnl.54.12.2261 · Cited by 870
Discrimination between Alzheimer dementia and controls by automated analysis of multicenter FDG PET
Herholz, K., Salmon, E., Perani, D., Baron, J.-C., Holthoff, V., Frölich, L., Schönknecht, P., Ito, K., Mielke, R., & Kalbe, E. (2002) · NeuroImage · doi:10.1006/nimg.2002.1208 · Cited by 832 · cited 6×
“…resulting in an accuracy between 86 and 100% (Hoffman et al., 1996; Arnaiz et al., 2001; Silverman et al., 2001, 2002b; Alexander et al., 2002; Herholz et al., 2002; Potkin Correspondence: Koen Van Laere MD PhD DrSc, Nuclear Medicine Division, UZ Gasthuisberg, Katholieke Universiteit Leuven,…”
BackgroundMethodInfluentialCerebral metabolic and cognitive decline in persons at genetic risk for Alzheimer’s disease
Small, G. W., Ercoli, L. M., Silverman, D. H. S., Huang, S.-C., Komo, S., Bookheimer, S. Y., Lavretsky, H., Miller, K., Siddarth, P., Rasgon, N. L., et al. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.090106797 · Cited by 790 · cited 1×
“Especially in view of the literature pointing towards the fact that PET can predict the rate of future decline based on cerebral metabolism (Small et al., 2000), it also diminishes the frustrations of equivocal or additional diagnostic test results.”
BackgroundSelf-citationMorris, J. C., Storandt, M., McKeel, D. W., Rubin, E. H., Price, J. L., Grant, E. A., & Berg, L. (1996) · Neurology · doi:10.1212/wnl.46.3.707 · Cited by 603 · cited 2×
“The diagnosis of probable Alzheimer’s disease (pAD) is often made on clinical grounds and especially in the early stages of the disease this can be difficult in differentiating it from other causes of mild cognitive impairment (MCI), depression or physiological cognitive decline normal with ageing (Bachman et al., 199…”
BackgroundAlexander, G. E., Chen, K., Pietrini, P., Rapoport, S. I., & Reiman, E. M. (2002) · American Journal of Psychiatry · doi:10.1176/appi.ajp.159.5.738 · Cited by 532
Incidence of dementia and probable Alzheimer's disease in a general population: The Framingham Study
Bachman, D. L., Wolf, P. A., Linn, R. T., Knoefel, J. E., Cobb, J. L., Belanger, A. J., White, L. R., & D'Agostino, R. B. (1993) · Neurology · doi:10.1212/wnl.43.3_part_1.515 · Cited by 470
Doody, R. S. (2001) · Archives of Neurology · doi:10.1001/archneur.58.3.427 · Cited by 362 · cited 1×
“We have used the standard methods for decision analysis (Drummond et al., 1997; Gambhir and Schwimmer, 2000) to quantify the major outcomes of this analysis: overall costs, costs per accurate diagnosis and number of accurate diagnoses.”
Method
Cited by
Herukka, S.-K., Simonsen, A. H., Andreasen, N., Baldeiras, I., Bjerke, M., Blennow, K., Engelborghs, S., Frisoni, G. B., Gabryelewicz, T., Galluzzi, S., et al. (2017) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2016.09.009 · Cited by 141
“The cost is relatively low [35,36], but LP requires personnel with the appropriate training and facilities.”
Recommendations for CSF AD biomarkers in the diagnostic evaluation of dementia
Simonsen, A. H., Herukka, S.-K., Andreasen, N., Baldeiras, I., Bjerke, M., Blennow, K., Engelborghs, S., Frisoni, G. B., Gabryelewicz, T., Galluzzi, S., et al. (2017) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2016.09.008 · Cited by 138
Dementia care costs and outcomes: a systematic review
Knapp, M., Iemmi, V., & Romeo, R. (2013) · International Journal of Geriatric Psychiatry · doi:10.1002/gps.3864 · Cited by 126
“A Belgian study, based on a decision tree design, found that F-fluorodeoxyglucose positron emission tomography (FDG PET) was cost-saving when added to standard diagnostic approaches because it had the potential to delay cognitive decline by allowing the more accurate prescription of medications (Moulin-Romsee et al.,…”
MethodFantoni, E. R., Chalkidou, A., O’ Brien, J. T., Farrar, G., & Hammers, A. (2018) · Journal of Alzheimer’s Disease · doi:10.3233/jad-171093 · Cited by 68
Clinical impact of a second FDG-PET in atypical/unclear dementia syndromes
Bergeron, D., Beauregard, J.-M., Guimond, J., Fortin, M.-P., Houde, M., Poulin, S., Verret, L., Bouchard, R. W., & Laforce, R. (2015) · Journal of Alzheimer's Disease · doi:10.3233/jad-150302 · Cited by 17
Metadata
- Authors
- Moulin‐Romsee, G., Maes, A., Silverman, D., Mortelmans, L., & Van Laere, K.
- Venue
- European Journal of Neurology
- Publisher
- Wiley
- Published
- 2005-03-17
- Volume
- 12
- Issue
- 4
- Pages
- 254-263
- ISSN
- 1351-5101 (ISSN-L)
- 1468-1331
- OpenAlex
- W2010064419
- Cited by
- 32
- References
- 11
- FWCI
- 0.73
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Cost‐effectiveness of 18F‐fluorodeoxyglucose positron emission tomography in the assessment of early dementia from a Belgian and European perspective. https://app.cochat.ai/papers/10.1111/j.1468-1331.2004.00940.x
- The paper
- Moulin‐Romsee, G., Maes, A., Silverman, D., Mortelmans, L., & Van Laere, K. (2005). Cost‐effectiveness of 18F‐fluorodeoxyglucose positron emission tomography in the assessment of early dementia from a Belgian and European perspective. European Journal of Neurology. https://doi.org/10.1111/j.1468-1331.2004.00940.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.